



NONALCOHOLIC STEATOHEPATITIS (NASH) A treatment for fibrotic disease

Applicant	Università degli Studi Padova
Inventors	Patrizia Pontisso, Alessandra Biasiolo, Andrea Cappon, Andrea Martini, Santina Quarta, Mariagrazia Ruvoletto, Cristian Turato, Gianmarco Villano
Priority Date	10/03/2017
Protection	IT Patent: IT102017000026858 US 16/491858 EP 18715258.2

TRL scale



What it is needed for?

Fibrosing diseases are chronic pathologies, with a different genesis, characterized by various types of cellular or extracellular infiltrates determining a progressive destruction of the parenchyma, which is replaced by fibrous tissue, causing progressive damage to organ anatomy. Fibrosing diseases are one of the main causes of morbidity and mortality in the Western world.

To date, no effective drugs are available for the treatment of such diseases.

This invention relates to a novel use of 1-piperidin propionic acid as drug for the treatment of fibrosing diseases. The compound acts on SerpinB3, which has been identified as an effective target, it reduces the expression of said molecule and limits fibrotic damage.

Advantages

- Novel drugable target in fibrotic diseases (SerpinB3);
- No targeted therapy towards SerpinB3 exist;
- Compound is well tolerated in the experimental model;
- Compound is stable in the experimental model;
- Compound is readily available on the market;
- Low cost.

Applications

A treatment for chronic fibrotic diseases, such as, Chronic Hepatitis, Steatohepatitis, Sclerosing Cholangitis, Cirrhosis of the liver, Cystic Fibrosis, Idiopathic Pulmonary Fibrosis, Kidney Fibrosis, and Connectivitis.

What we are looking for

Technology is available for licensing and/or co-development